Trial Profile
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms ADAPTeR
- 01 Oct 2019 Status changed from recruiting to active, no longer recruiting as per the results presented at the 44th European Society for Medical Oncology Congress.
- 23 Mar 2018 Planned primary completion date changed from 1 Nov 2016 to 1 May 2018.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology